You are here

Statistically Significant Improvement in Survival Demonstrated in Abraxane Study

SCHAUMBURG, Ill., February 25, 2005 /PRNewswire-FirstCall American Pharmaceutical Partners, Inc. (Nasdaq: APPX), today announced that the pivotal Phase III clinical study of Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in patients with metastatic breast cancer demonstrated a statistically significant improvement in survival in second-line patients. The data were presented at the 22nd Annual Miami Breast Cancer Conference in Miami, FL, by Edith Perez, M.D., Professor of Medicine, Mayo Clinic College of Medicine, Chair Breast Committee, North Central Cancer Treatment Group. Dr. Perez's presentation of new anti-tubulin agents included for the first time an initial analysis of survival data from the prospectively randomized trial of 460 patients with metastatic breast cancer.

The study population included patients who were previously untreated and those who were previously treated (second-line or greater-line therapy) for metastatic breast cancer. In the overall patient population, median survival for those patients receiving ABRAXANE was 10 weeks longer (65.0 weeks v. 55.7 weeks) than for patients receiving Taxol but this difference did not reach statistical significance. However there was a significant prolongation in survival (p=0.016) in patients receiving Abraxane in the second-line or greater setting as compared to those receiving Taxol (56.4 weeks vs. 46.7 weeks). In this group, there was a 29% reduction in the risk of death (i.e., hazard ratio of 0.71) for patients who received Abraxane compared to those who received Taxol.

Abraxane consists only of albumin-bound paclitaxel nanoparticles and no toxic solvents. As previously reported, in the Phase III clinical study, Abraxane demonstrated a superior response rate with an almost doubling of the reconciled target lesion response rate when compared with the solvent-based Taxol®. Because it contains no toxic solvents, this next-generation taxane product enables the administration of 50% more chemotherapy with a well-tolerated safety profile, requires no premedication to prevent hypersensitivity reactions and can be given over 30 minutes using standard IV tubing. The Phase III study was designed to compare ABRAXANETM at a dose of 260 mg/m2 given as a 30-minute infusion without premedication to paclitaxel injection (Taxol®) at 175 mg/m2 given as a 3-hour infusion with standard steroid and antihistamine premedication.

Abraxane was launched on February 7, 2005 by Abraxis Oncology, the proprietary division of APP after having received FDA approval in January. Abraxane is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Source: American Pharmaceutical Partners, Inc.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function
U.S. maintains measles elimination status as NY outbreak ebbs
Study lists steps that could save close to $300 billion a year